Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

terminated133%
unknown133%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_2

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

NCT04803877
unknown

A Real World Study of Regogfinib in HCC

NCT05557656
terminatedphase_2

Optimization for Regorafenib in HCC

NCT04476329

Clinical Trials (3)

Showing 3 of 3 trials
NCT04803877Phase 2

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Active Not Recruiting
NCT05557656

A Real World Study of Regogfinib in HCC

Unknown
NCT04476329Phase 2

Optimization for Regorafenib in HCC

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3